Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of OC000459 on eosinophilic airway inflammation and asthma control in refractory eosinophilic asthma
2015-001833-26Phase 2Completed
- Sponsor
- Atopix Therapeutics
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing OC000459 with Placebo (2 arms). Primary endpoint: Induced sputum eosinophil fold change at 12 weeks. Started Jul 2015; status: completed.
02
Drugs
timapiprant
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2015-001833-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001833-26.